Literature DB >> 16126226

Rationalising lysozyme amyloidosis: insights from the structure and solution dynamics of T70N lysozyme.

Russell J K Johnson1, John Christodoulou, Mireille Dumoulin, Gemma L Caddy, Marcos J C Alcocer, Gareth J Murtagh, Janet R Kumita, Göran Larsson, Carol V Robinson, David B Archer, Ben Luisi, Christopher M Dobson.   

Abstract

T70N human lysozyme is the only known naturally occurring destabilised lysozyme variant that has not been detected in amyloid deposits in human patients. Its study and a comparison of its properties with those of the amyloidogenic variants of lysozyme is therefore important for understanding the determinants of amyloid disease. We report here the X-ray crystal structure and the solution dynamics of T70N lysozyme, as monitored by hydrogen/deuterium exchange and NMR relaxation experiments. The X-ray crystal structure shows that a substantial structural rearrangement results from the amino acid substitution, involving residues 45-51 and 68-75 in particular, and gives rise to a concomitant separation of these two loops of up to 6.5A. A marked decrease in the magnitudes of the generalised order parameter (S2) values of the amide nitrogen atom, for residues 70-74, shows that the T70N substitution increases the flexibility of the peptide backbone around the site of mutation. Hydrogen/deuterium exchange protection factors measured by NMR spectroscopy were calculated for the T70N variant and the wild-type protein. The protection factors for many of backbone amide groups in the beta-domain of the T70N variant are decreased relative to those in the wild-type protein, whereas those in the alpha-domain display wild-type-like values. In pulse-labelled hydrogen/deuterium exchange experiments monitored by mass spectrometry, transient but locally cooperative unfolding of the beta-domain of the T70N variant and the wild-type protein was observed, but at higher temperatures than for the amyloidogenic variants I56T and D67H. These findings reveal that such partial unfolding is an intrinsic property of the human lysozyme structure, and suggest that the readiness with which it occurs is a critical feature determining whether or not amyloid deposition occurs in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126226     DOI: 10.1016/j.jmb.2005.07.040

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  15 in total

1.  A non-natural variant of human lysozyme (I59T) mimics the in vitro behaviour of the I56T variant that is responsible for a form of familial amyloidosis.

Authors:  Christine L Hagan; Russell J K Johnson; Anne Dhulesia; Mireille Dumoulin; Janice Dumont; Erwin De Genst; John Christodoulou; Carol V Robinson; Christopher M Dobson; Janet R Kumita
Journal:  Protein Eng Des Sel       Date:  2010-04-09       Impact factor: 1.650

2.  Molecular origin of the self-assembly of lanreotide into nanotubes: a mutational approach.

Authors:  Céline Valéry; Emilie Pouget; Anjali Pandit; Jean-Marc Verbavatz; Luc Bordes; Isabelle Boisdé; Roland Cherif-Cheikh; Franck Artzner; Maité Paternostre
Journal:  Biophys J       Date:  2007-11-09       Impact factor: 4.033

Review 3.  Amyloid formation by globular proteins under native conditions.

Authors:  Fabrizio Chiti; Christopher M Dobson
Journal:  Nat Chem Biol       Date:  2009-01       Impact factor: 15.040

4.  Local cooperativity in an amyloidogenic state of human lysozyme observed at atomic resolution.

Authors:  Anne Dhulesia; Nunilo Cremades; Janet R Kumita; Shang-Te Danny Hsu; Maria F Mossuto; Mireille Dumoulin; Daniel Nietlispach; Mikael Akke; Xavier Salvatella; Christopher M Dobson
Journal:  J Am Chem Soc       Date:  2010-11-10       Impact factor: 15.419

5.  Switch region for pathogenic structural change in conformational disease and its prediction.

Authors:  Xin Liu; Ya-Pu Zhao
Journal:  PLoS One       Date:  2010-01-11       Impact factor: 3.240

6.  Activation of innate immunity by lysozyme fibrils is critically dependent on cross-β sheet structure.

Authors:  Adelin Gustot; Vincent Raussens; Morgane Dehousse; Mireille Dumoulin; Clare E Bryant; Jean-Marie Ruysschaert; Caroline Lonez
Journal:  Cell Mol Life Sci       Date:  2013-01-19       Impact factor: 9.261

7.  A nanobody binding to non-amyloidogenic regions of the protein human lysozyme enhances partial unfolding but inhibits amyloid fibril formation.

Authors:  Erwin De Genst; Pak-Ho Chan; Els Pardon; Shang-Te D Hsu; Janet R Kumita; John Christodoulou; Linda Menzer; Dimitri Y Chirgadze; Carol V Robinson; Serge Muyldermans; André Matagne; Lode Wyns; Christopher M Dobson; Mireille Dumoulin
Journal:  J Phys Chem B       Date:  2013-09-24       Impact factor: 2.991

8.  Analysis of the native structure, stability and aggregation of biotinylated human lysozyme.

Authors:  Minkoo Ahn; Erwin De Genst; Gabriele S Kaminski Schierle; Miklos Erdelyi; Clemens F Kaminski; Christopher M Dobson; Janet R Kumita
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

9.  Disease-related amyloidogenic variants of human lysozyme trigger the unfolded protein response and disturb eye development in Drosophila melanogaster.

Authors:  Janet R Kumita; Linda Helmfors; Jocy Williams; Leila M Luheshi; Linda Menzer; Mireille Dumoulin; David A Lomas; Damian C Crowther; Christopher M Dobson; Ann-Christin Brorsson
Journal:  FASEB J       Date:  2011-09-29       Impact factor: 5.191

10.  Investigating the physiological response of Pichia (Komagataella) pastoris GS115 to the heterologous expression of misfolded proteins using chemostat cultures.

Authors:  Andrew R Hesketh; Juan I Castrillo; Trevor Sawyer; David B Archer; Stephen G Oliver
Journal:  Appl Microbiol Biotechnol       Date:  2013-09-11       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.